IIFL View
Go
  • Berger Paints

    BPIL's domestic volume growth in Q1FY19 accelerated 15%, which was higher than that of industry leader APNT, and helped BPL register sector leading revenue growth of 18.9% yoy. However, inspite of stellar top line growth, BPL’s gross margin fo...

    Reduce Reco. Price: 333.50

  • Bosch

    Bosch’s Q1FY19 results were in-line with estimates with revenue and EBITDA up 21% yoy and 43% yoy respectively and EBITDA margin expansion of 298bps yoy to 19.6%. Despite rising input costs, the company has been on a major cost cutting spree,...

    Accumulate Reco. Price: 18,866.45

  • Glaxosmit Pharma

    GlaxoSmithKline Pharmaceuticals GSK has recently launched Neosporin, EnteroPlus (probiotic brand) and Priorix Tetra (first Measles, Mumps, Rubella and Varicella vaccine in India). GSK expects to grow organically (launch innovative global pipeline drugs) and...

    Sell Reco. Price: 3,303.40

  • Abbott India

    We estimate revenue/PAT CAGR of 16.3%/22.3% respectively over FY18-20E owing to (a) new product launches in India (b) entry in the high margin vaccine segment and (c) high brand recall in the existing products. Company also distributes Novo Nordisk’s ...

    Accumulate Reco. Price: 7,822.00

  • Deepak Nitrite

    Deepak Nitrite (DNL) has invested Rs140cr in the phenol-acetone facility, which has huge demand across several sectors (currently imported in India). This facility would lead to market share opportunity of 60-63% of the total demand in India. The facility i...

    Buy Reco. Price: 276.00

  • Adani Ports

    APSEZ intends to commercialise its fleet of 19 dredgers in order to drive its revenue. APSEZ is expected to see improved earnings momentum owing to (a) improvement in the cargo volumes, (b) strong growth in the container volumes, and (c) better crude volume...

    Buy Reco. Price: 373.95

  • Sanofi India

    We project company to report revenue/PAT CAGR of 15%/20.2% over CY17-19E owing to strong brand equity, double digit growth in prescription brands (Lantus, Allegra, etc.) and stable growth in OTC brands (DePura, Collaflex, etc). The growth of diabetes in Ind...

    Accumulate Reco. Price: 6,380.00

  • Gulf Oil Lubric.

    Gulf Oil Lubricants (GOL) has been gaining market share in the lubricant industry and is expected to sustain its momentum on the back of increased OEM tie-ups. Moreover, increased focus on the personal mobility segment would drive volumes (~33% volume growt...

    Buy Reco. Price: 822.00

  • Max India

    Its hospital business would benefit from expansion of bed capacity from 2,570 beds in FY18 to 5,810 beds by FY23E. Company focuses on improving its specialty healthcare services, which provides higher margins vs. low margin primary healthcare services. Its ...

    Accumulate Reco. Price: 89.15

  • Cadila Health.

    Cadila has strong ANDA pipeline (185 approved, 135 pending) and expects about 40 product launches in FY18. The FY19E launches of gAsacol, and gToprol XL are not likely to offset the lost market share in gLialda/gTamiflu due to competition. Cadila’s US...

    Reduce Reco. Price: 356.80